Treanda is owned by Cephalon.
Treanda contains Bendamustine Hydrochloride.
Treanda has a total of 18 drug patents out of which 0 drug patents have expired.
Treanda was authorised for market use on 20 March, 2008.
Treanda is available in solution;iv (infusion), powder;iv (infusion) dosage forms.
Treanda can be used as for use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl), for use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; for use in the treatment of patients with chronic lymphocytic leukemia (cll), for use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma.
The generics of Treanda are possible to be released after 26 April, 2031.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8445524 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
US8609863 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(2 years from now) | |
US8609863
(Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
US8791270
(Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
US8895756
(Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Jul, 2026
(3 years from now) | |
US8883836 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(6 years from now) | |
US9533955 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(6 years from now) | |
US8669279 | CEPHALON | Solid forms of bendamustine hydrochloride |
Mar, 2029
(6 years from now) | |
US8344006 | CEPHALON | Liquid formulations of bendamustine |
Sep, 2029
(6 years from now) | |
US9533955
(Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
US8883836
(Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
US8669279
(Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
US8445524
(Pediatric) | CEPHALON | Solid forms of bendamustine hydrochloride |
Sep, 2029
(6 years from now) | |
US8344006
(Pediatric) | CEPHALON | Liquid formulations of bendamustine |
Mar, 2030
(7 years from now) | |
US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(7 years from now) | |
US8436190
(Pediatric) | CEPHALON | Bendamustine pharmaceutical compositions |
Apr, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
ODE* (ODE*) | Dec 7, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 20 March, 2008
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl); For use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll)
Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)
37
United States
7
China
6
Australia
6
European Union
5
Japan
4
Mexico
4
Korea, Republic of
3
Hong Kong
3
Canada
2
Spain
2
Argentina
2
Taiwan, Province of China
1
Singapore
1
Malaysia
1
Brazil
1
New Zealand
1
Norway
1
EA
1
South Africa
1
Ukraine
1
Chile
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic